Sep 30, 2026 from The Cancer News Leptomeningeal Disease Is Becoming More Common, and Also More Treatable Explore leptomeningeal disease updates: EGFR/ALK targeted therapies, NCCN CSF ctDNA testing guidelines, and proton craniospinal irradiation.
Sep 30, 2026 from Your Local Epidemiologist When “DEI” research is cut, what happens to community health? Health equity is caught in the crossfire
Sep 29, 2026 from Your Local Epidemiologist Flu is here early. Plus Covid, mosquitoes, and more. The Dose (Sept 29)
Sep 28, 2026 from The Cancer News Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show Explore multiple myeloma updates: CAR-T vs. bispecific sequencing, T-cell exhaustion factors, IVIG infection prophylaxis, and dual-antigen strategies.
Sep 25, 2026 from Your Local Epidemiologist Don’t boil the ocean: Reach passive positives The 2026 fall vaccines should be available, for free, to everyone who needs them.
Sep 23, 2026 from Your Local Epidemiologist Medicare for All: Separating the slogan from the substance People are fed up with the U.S.
Sep 22, 2026 from Your Local Epidemiologist Where are the fall vaccines? Plus Covid-19 and norovirus, and what another measles death means The Dose (Sept 22)
Sep 21, 2026 from The Cancer News At-Home Cervical Cancer Screening Kits Outperform Office-Based Approach in Under-Resourced Settings New research from MD Anderson finds mailed HPV screening kits more effective than clinic-based exams, offering a game-changing solution to reduce cervical cancer disparities in underserved and glob...
Sep 19, 2026 from The Cancer News Precision Frontiers in Hepatobiliary Oncology: FGFR2 Selectivity and Immunotherapy in HCC and iCCA Explore how FGFR2-selective therapy is reshaping iCCA treatment and why immunotherapy strategies in HCC are shifting away from adjuvant use toward perioperative and first-line approaches.
Sep 18, 2026 from Your Local Epidemiologist Two days left to comment on HHS's vaccine category proposal Okay, this one’s a bit in the weeds, but it’s worth your attention.
Sep 17, 2026 from The Cancer News Autologous Transplant in Multiple Myeloma: Still the Standard as Quadruplet Therapy and Cellular Immunotherapy Advance Explore multiple myeloma updates: ASCT role in the PERSEUS quadruplet era, MRD-guided maintenance, and CAR-T/bispecific competition at relapse.
Sep 17, 2026 from The Cancer News Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment Meta Description Explore head and neck cancer updates: KEYNOTE-689 perioperative pembrolizumab, NIVOPOSTOP data, and amivantamab in 2nd-line HPV-negative disease
Sep 17, 2026 from The Cancer News Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation Explore prostate cancer updates: perioperative apalutamide in PROTEUS, TALAPRO-3 talazoparib HRR/ATM data, ARPI cognitive profiles, and ADT pauses.
Sep 16, 2026 from Your Local Epidemiologist What AI can and cannot do in biosecurity And what needs to happen
Sep 15, 2026 from The Cancer News Overcoming Language Barriers in Cancer Care Language barriers delay cancer diagnoses and lower screening rates. Experts explain why interpreter access and cultural competence matter for LEP patients.
Sep 15, 2026 from The Cancer News The New Frontier in Lung Cancer Therapy: Targeted Therapy, and Bispecific Antibodies. Explore lung cancer data: adjuvant selpercatinib in RET+ NSCLC, ANVIL trial limits, and bispecific antibodies (tarlatamab, ivonescimab) in 2nd-line SCLC.
Sep 15, 2026 from The Cancer News MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices Explore high-risk MDS, MECOM-rearranged AML, and BPDCN data: VERONA trial venetoclax results, transplant roles, and emerging BPDCN therapies.
Sep 15, 2026 from The Cancer News Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Pausing Treatment Explore ASCO 2026 prostate cancer updates: perioperative apalutamide, PTEN and HRR biomarker regimens, and data supporting safe treatment breaks.
Sep 15, 2026 from The Cancer News Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Smoldering Disease Care Discover ASCO 2026 multiple myeloma breakthroughs, including early teclistamab, mezigdomide CELMoD data, in vivo CAR-T, and smoldering disease trials.
